Table 3.
Patient Characteristics, MRCP Scores, and Clinical Outcomes
| n (%) or Median (IQR) | All PSC | Sum IHD‐EHD Score ≥4 | Sum IHD‐EHD Score <4 | P Value |
|---|---|---|---|---|
| (n = 45) | (n = 10) | (n = 35) | ||
| Male | 30 (67%) | 6 (60%) | 24 (69%) | 0.71 |
| Age at diagnosis (years) | ||||
| PSC | 13.6 (10.3‐15.2) | 12.4 (7.8‐16.0) | 13.6 (10.3‐15.2) | 0.73 |
| IBD | 13.5 (10.1‐15.5) | 11.2 (4.7‐15.7) | 13.5 (10.8‐15.5) | 0.38 |
| PSC follow‐up duration (years) | 3.4 (2.4‐4.4) | 2.8 (2.4‐5.3) | 3.5 (2.1‐4.3) | 0.99 |
| Ulcerative colitis/IBD‐U | 35 (78%) | 9 (90%) | 26 (74%) | 0.39 |
| Crohn’s disease | 5 (11%) | 1 (10%) | 4 (11%) | |
| No IBD | 5 (11%) | 0 | 5 (14%) | |
| ASC | 12 (27%) | 2 (20%) | 10 (29%) | 0.71 |
| Small‐duct PSC | 4 (9%) | 10 (100%) | 4 (11%) | 0.56 |
| Biochemistry at time of MRCP | ||||
| ALT (U/L) | 75 (46‐166) | 128 (50‐210) | 73 (44‐159) | 0.37 |
| AST (U/L) | 70 (40‐201) | 177 (56‐371) | 59 (37‐142) | 0.09 |
| ALP (U/L) | 361 (169‐685) | 642 (260‐1003) | 332 (149‐565) | 0.05 |
| GGT (U/L) | 189 (73‐403) | 331 (94‐495) | 188 (55‐356) | 0.20 |
| Total bilirubin (µmol/L) | 9 (6‐19) | 20 (7‐45) | 9 (6‐15) | 0.14 |
| Albumin (g/L) | 42 (40‐45) | 42 (38‐45) | 42 (40‐45) | 0.46 |
| Platelets (×109/L) | 311 (231‐424) | 309 (199‐479) | 311 (234‐424) | 0.92 |
| METAVIR fibrosis closest to MRCP | 2 (1‐3) | 2.5 (2‐4) | 1 (1‐2) | 0.02 |
| F0 | 6 (13%) | 0 | 6 (17%) | |
| F1 | 15 (33%) | 1 (10%) | 14 (40%) | |
| F2 | 12 (27%) | 4 (40%) | 8 (23%) | |
| F3 | 7 (16%) | 2 (20%) | 5 (14%) | |
| F4 | 5 (11%) | 3 (30%) | 2 (6%) | |
| PSC MRS | −0.97 (−1.8‐−0.33) | −0.09 (−1.8‐0.85) | −1.3 (−1.8‐−0.47) | 0.087 |
| IHD score | – | – | – | |
| 0 | 4 (9%) | |||
| 1 | 20 (44%) | |||
| 2 | 17 (38%) | |||
| 3 | 4 (9%) | |||
| EHD score* | – | – | – | |
| 0 | 17 (40%) | |||
| 1 | 12 (28%) | |||
| 2 | 9 (21%) | |||
| 3 | 5 (12%) | |||
| 4 | 0 | |||
| Sum IHD‐EHD score | – | – | – | |
| 0 | 4 (9%) | |||
| 1 | 7 (16%) | |||
| 2 | 15 (33%) | |||
| 3 | 9 (20%) | |||
| 4 | 5 (11%) | |||
| 5 | 3 (7%) | |||
| 6 | 2 (4%) | |||
| 7 | 0 | |||
| Average IHD score | 1 (1‐1.6) | – | – | – |
| Average EHD score | 0.5 (0‐1.5) | – | ||
| Sum average IHD‐EHD score | 1.9 (1‐2.5) | – | – | – |
| Portal hypertension | 15 (33%) | 7 (70%) | 8 (23%) | 0.009 |
| Ascites | 5 (11%) | 3 (30%) | 2 (6%) | 0.065 |
| Esophageal varices | 8 (18%) | 4 (40%) | 4 (11%) | 0.059 |
| Variceal bleed | 4 (9%) | 2 (20%) | 2 (6%) | 0.21 |
| Cholangiocarcinoma | 1 (2%) | 1 (10%) | 0 | 0.22 |
| Liver transplant | 5 (11%) | 5 (50%) | 0 | <0.001 |
| PSC‐related complication | 10 (22%) | 6 (60%) | 4 (11%) | 0.004 |
*
Two MRCPs could not be examined for extrahepatic involvement.